Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T16:11:12.094Z.
Calculation as of: 2026-10-06T16:11:12.094Z.
Quote observation: 2026-10-06T16:10:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: efaaa36d31f915a5dffaa91b800fc30e2d7f64892a7236e7a1e7b68ff3f7d584
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Crescent Biopharma, Inc.
Market Cap
$522.80M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$523.00M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$520.22M
Free Cash Flow Yield
N/A
TTM Avg
536.25%
3Y Avg
536.25%
5Y Avg
536.25%
Market Cap
$534.01M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$509.64M
Free Cash Flow Yield
0.09%
TTM Avg
0.12%
3Y Avg
0.12%
5Y Avg
0.12%
Market Cap
$539.40M
Free Cash Flow Yield
3.25%
TTM Avg
3.62%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$542.49M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$503.89M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | $522.80M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $523.00M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $520.22M | N/A | 536.25% | 536.25% | 536.25% |
| Immix Biopharma, Inc. (IMMX)vs › | $534.01M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.22M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $509.64M | 0.09% | 0.12% | 0.12% | 0.12% |
| Delcath Systems, Inc. (DCTH)vs › | $539.40M | 3.25% | 3.62% | 3.23% | 3.23% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $542.49M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $503.89M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $549.58M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
